Beth Apsel Winger, MD, PhD
Assistant Professor
Clinical Pharmacy
School of Pharmacy

Dr. Winger’s research is focused on advancing precision medicine to improve therapeutics and outcomes for patients with cancer and other blood diseases. Her research has two main focuses: 1) understanding mutations in kinases so that we can expand the use of targeted therapies and match the right drug to the right patient, and 2) developing precision dosing strategies to give every patient the right amount of drug for their body.

Publications (20)

Top publication keywords:
PiebaldismChimerismProtein Kinase InhibitorsBusulfanPyrazolesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaImmunocompromised HostMelphalanProstaglandins EStaurosporineEnterocolitisLeukemiaProto-Oncogene Proteins c-kitTriazinesMycobacterium bovis

• Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Paolino J, Dimitrov B, Apsel Winger B, Sandoval-Perez A, Rangarajan AV, Ocasio-Martinez N, Tsai HK, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Polonen P, Dilig A, Gotti G, Kavanagh J, Adhav AA…
• EML4::ALK fusions in complex lymphatic malformations.
  Pediatric blood & cancer 2023 Apsel Winger B, Devine WP, Hsiao EC, Zapala M, Van Ziffle J, Gupta N, Frieden IJ, Shimano KA
• Correction to "Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations".
  Journal of chemical theory and computation 2022 Sandoval-Pérez A, Winger BA, Jacobson MP
• Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.
  Journal of chemical theory and computation 2022 Sandoval-Pérez A, Winger BA, Jacobson MP
• Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
  Journal of chromatography open 2022 Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J

Show all (15 more) Hide

• Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
  Journal of clinical pharmacology 2022 Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Apsel Winger B
• A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults.
  Frontiers in pediatrics 2021 Apsel Winger B, Long SE, Brooks J, Gupta AO, Dvorak CC, Long-Boyle JR
• Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
  Cancer discovery 2021 Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee …
• The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders.
  Transplantation and cellular therapy 2020 Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, Dvorak CC, Long-Boyle J
• Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
  Frontiers in pharmacology 2020 Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J
• Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
  Journal of clinical pharmacology 2020 Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V
• ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
  Cancer research 2019 Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP
• Mycobacterium bovis Enterocolitis in an Immunocompromised Host.
  Journal of pediatric gastroenterology and nutrition 2016 Winger BA, Foy E, Sud SR, MacKenzie JD, Pua HH, Lau AH, Heyman MB, Laszik Z, Tureen J
• PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
  Cancer cell 2015 Apsel Winger B, Shah NP
• Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
  PLoS biology 2009 Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM
• Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
  Nature chemical biology 2008 Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA
• Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.
  Cancer cell 2008 Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM
• Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei.
  Chemical biology & drug design 2006 Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH
• Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA.
  British journal of pharmacology 2004 Pillinger MH, Dinsell V, Apsel B, Tolani SN, Marjanovic N, Chan ES, Gomez P, Clancy R, Chang LF, Abramson SB
• Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation.
  Journal of immunology (Baltimore, Md. : 1950) 2003 Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, Chan ES, Gomez PF, Abramson SB